BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)

Author
Debled, M.
Hegg, R.
Cardoso, F.
Ringeisen, F.
Lin, J.
Ridolfi, A.
Manlius, C.
Gradishar, W. J.
Ozguroglu, M.
Royce, M.
Villanueva, C.
Bachelot, T.
Azevedo, S.
Melo Cruz, F.
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/92345
https://doi.org/10.1093/annonc/mdw365.1
Collections